145 related articles for article (PubMed ID: 23148755)
1. Dendritic cell-based vaccination for renal cell carcinoma: challenges in clinical trials.
Wang J; Liao L; Tan J
Immunotherapy; 2012 Oct; 4(10):1031-42. PubMed ID: 23148755
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma.
Berntsen A; Geertsen PF; Svane IM
Eur Urol; 2006 Jul; 50(1):34-43. PubMed ID: 16675096
[TBL] [Abstract][Full Text] [Related]
3. Vaccine therapy in patients with renal cell carcinoma.
Van Poppel H; Joniau S; Van Gool SW
Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
[TBL] [Abstract][Full Text] [Related]
4. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids.
Kugler A; Stuhler G; Walden P; Zöller G; Zobywalski A; Brossart P; Trefzer U; Ullrich S; Müller CA; Becker V; Gross AJ; Hemmerlein B; Kanz L; Müller GA; Ringert RH
Nat Med; 2000 Mar; 6(3):332-6. PubMed ID: 10700237
[TBL] [Abstract][Full Text] [Related]
5. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.
Soleimani A; Berntsen A; Svane IM; Pedersen AE
Scand J Immunol; 2009 Nov; 70(5):481-9. PubMed ID: 19874553
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell vaccines in melanoma: from promise to proof?
Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell-tumor fusion vaccines for renal cell carcinoma.
Avigan D
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6347S-52S. PubMed ID: 15448029
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma.
Märten A; Renoth S; Heinicke T; Albers P; Pauli A; Mey U; Caspari R; Flieger D; Hanfland P; Von Ruecker A; Eis-Hübinger AM; Müller S; Schwaner I; Lohmann U; Heylmann G; Sauerbruch T; Schmidt-Wolf IG
Hum Gene Ther; 2003 Mar; 14(5):483-94. PubMed ID: 12691613
[TBL] [Abstract][Full Text] [Related]
9. Tumor cell-based vaccination in renal cell carcinoma: rationale. approaches, and recent clinical development.
Volk J; Sel S; Ganser A; Schöffski P
Curr Drug Targets; 2002 Oct; 3(5):401-8. PubMed ID: 12182231
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival of patients with metastatic renal cell carcinoma treated with pulsed dendritic cells.
Kraemer M; Hauser S; Schmidt-Wolf IG
Anticancer Res; 2010 Jun; 30(6):2081-6. PubMed ID: 20651354
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
12. Current immunotherapeutic strategies in renal cell carcinoma.
Amato RJ
Surg Oncol Clin N Am; 2007 Oct; 16(4):975-86, xi-xii. PubMed ID: 18022554
[TBL] [Abstract][Full Text] [Related]
13. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
[TBL] [Abstract][Full Text] [Related]
14. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
Saha A; Chatterjee SK
Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858
[TBL] [Abstract][Full Text] [Related]
15. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2.
Berntsen A; Brimnes MK; thor Straten P; Svane IM
J Immunother; 2010 May; 33(4):425-34. PubMed ID: 20386464
[TBL] [Abstract][Full Text] [Related]
16. Matched-pair analysis of dendritic cell versus targeted-therapy in patients with metastatic renal cell carcinoma.
Isaak A; Hauser S; Rogenhofer S; Schmidt-Wolf IG
Anticancer Res; 2015 Mar; 35(3):1575-82. PubMed ID: 25750313
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?
Bedke J; Stenzl A
Expert Rev Anticancer Ther; 2013 Dec; 13(12):1399-408. PubMed ID: 24215158
[TBL] [Abstract][Full Text] [Related]
18. Antigen-independent immune responses after dendritic cell vaccination.
Leonhartsberger N; Ramoner R; Putz T; Gander H; Rahm A; Falkensammer C; Bartsch G; Thurnher M
Cancer Immunol Immunother; 2007 Jun; 56(6):897-903. PubMed ID: 17106716
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma.
Zhan HL; Gao X; Pu XY; Li W; Li ZJ; Zhou XF; Qiu JG
Chin Med J (Engl); 2012 Nov; 125(21):3771-7. PubMed ID: 23106871
[TBL] [Abstract][Full Text] [Related]
20. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells.
Höltl L; Rieser C; Papesh C; Ramoner R; Herold M; Klocker H; Radmayr C; Stenzl A; Bartsch G; Thurnher M
J Urol; 1999 Mar; 161(3):777-82. PubMed ID: 10022683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
